Ansun BioPharma

company

About

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$85M
Industries
Biopharma,Biotechnology,Clinical Trials,Health Care,Medical
Founded date
Jan 1, 2003
Number Of Employee
1 - 10
Operating Status
Active

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.

The company was founded in 2003 and is headquartered in San Diego, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$185M
Ansun BioPharma has raised a total of $185M in funding over 2 rounds. Their latest funding was raised on Oct 15, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 15, 2019 Series B $100M 1 Detail
May 14, 2018 Series A $85M 2 Lilly Asia Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Ansun BioPharma is funded by 2 investors. Lilly Asia Ventures and Joincap Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series B
Joincap Investment Series A